The postoperative Model for End stage Liver Disease score as a predictor of short-term outcome after transplantation of extended criteria donor livers

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):716-722. doi: 10.1097/MEG.0000000000000851.

Abstract

Background: Recently, the postoperative Model for End stage Liver Disease score (POPMELD) was suggested as a definition of postoperative graft dysfunction and a predictor of outcome after liver transplantation (LT).

Aim: The aim of the present study was to validate this concept in the context of extended criteria donor (ECD) organs.

Patients and methods: Single-center prospectively collected data (OPAL study/01/11-12/13) of 116 ECD LTs were utilized. For each recipient, the Model for End stage Liver Disease (MELD) score was calculated for 7 postoperative days (PODs). The ability of international normalized ratio, bilirubin, aspartate aminotransferase, Donor Risk Index, a recent definition of early allograft dysfunction, and the POPMELD was compared to predict 90-day graft loss. Predictive abilities were compared by receiver operating characteristic curves, sensitivity and specificity, and positive and negative predictive values.

Results: The median Donor Risk Index was 1.8. In all, 60.3% of recipients were men [median age of 54 (23-68) years]. The median POD1-7 peak-aspartate aminotransferase value was 1052 (194-17 577) U/l. The rate of early allograft dysfunction was 22.4%. The 90-day graft survival was 89.7%. Out of possible predictors of the 90-day graft loss MELD on POD5 was the best predictor of outcome (area under the curve=0.84). A MELD score of 16 or more on POD5 predicted the 90-day graft loss with a specificity of 80.8%, a sensitivity of 81.8%, and a positive and negative predictive value of 31 and 97.7%.

Conclusion: A MELD score of 16 or more on POD5 is an excellent predictor of outcome in ECD donor LT. Routine evaluation of POPMELD scores might support clinical decision-making and should be reported routinely in clinical trials.

Publication types

  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Area Under Curve
  • Aspartate Aminotransferases / blood
  • Bilirubin / blood
  • Biomarkers / blood
  • Decision Support Techniques*
  • Donor Selection*
  • Female
  • Germany
  • Graft Survival*
  • Humans
  • International Normalized Ratio
  • Kaplan-Meier Estimate
  • Liver Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Primary Graft Dysfunction / diagnosis
  • Primary Graft Dysfunction / etiology*
  • ROC Curve
  • Randomized Controlled Trials as Topic
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Tissue Donors / supply & distribution*
  • Treatment Outcome
  • Young Adult

Substances

  • Biomarkers
  • Aspartate Aminotransferases
  • Bilirubin